FDA Grants Import Discretion of Bracco's Iodinated Contrast Medium

Bracco Diagnostics Inc. has announced that the U.S. Food and Drug Administration (FDA) granted import discretion of Iomeron (iomeprol injection) into the U.S. to address the ongoing iodinated contrast media shortage. The product addresses the need for the most advanced diagnostic imaging standards and will be temporarily available in the U.S. market starting at the end of August, 2022.

Generic, FDA approved contrast agent set to hit the market in wake of nationwide shortage

FDA Clears Ziehm Vision RFD Mobile C-Arm for Endovascular, Interventional Cardiology

articles • APPLIED RADIOLOGY

Bracco Diagnostics Unveils Contrast Media and Device Offerings at RSNA 2019 - RSNA 2019 - mobile.

articles • APPLIED RADIOLOGY

FDA to Allow Bracco to Import Iomeron Iodinated Contrast Media as Shortage Drags On

S-1

Computed Tomography (CT)

Short-, Mid-, and Long-term Strategies to Manage the Shortage of Iohexol

Bracco Acquires Contrast Injector Maker Swiss Medical Care

Siemens Healthineers Announces FDA Clearance of ARTIS icono ceiling Angiography System

Contrast Media Imaging Technology News

Contrast Media Imaging Technology News - 阿根廷vs乌拉圭直播

FDA approves Gadopiclenol injection for the U.S. market

Portable DR Available for Patient Bedside